Does in patients with type 2 diabetes and renal failure treated with dialysis can be used to treat blockers DPP-4?

Abstract

Diabetes is a scourge beginning of the XXI century. Diabetes leads to the development of late complications with reduce the quality of life and reduce the expected survival curve. In the course of diabetes many subjects come to develop ESRD. These patients are then treated with renal replacement therapy, especially hemodialysis. We just give the questions: 1. does in patients with type 2 diabetes treated with hemodialysis may be used in the treatment of blockers dipeptidyl peptidase-4 (DPP-4 blockers)? and 2. what is the effect of such therapeutic treatment?

At the present time worldwide available are 7 blockers DPP-4. In Poland, patients have access only to 4 of them (sitagliptyn, vildagliptin, saxagliptin and linagliptyn). It should be emphasized that these drugs from the group of DPP-4 blockers may be used in patients with type 2 diabetes on hemodialysis. The paper discusses the properties of individual drugs in this group, and then presents the effectiveness of DPP-4 blockers in patients with type 2 diabetes treated with hemodialysis, both alone and in combination therapy.

In the following part of the study presents the impact on other parameters of glucose metabolism and shows anti-inflammatory effect and tolerability and safety measures DPP-4 blockers.